Kazia Therapeutics Ltd ADR KZIA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $12.54
- Day Range
- $12.60–14.41
- 52-Week Range
- $4.86–17.40
- Bid/Ask
- $14.30 / $14.93
- Shares Outstanding
- 11.43M
- Market Cap
- $163.18M
- Volume/Avg
- 167,825 / 214,104
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 960.34
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Kazia Therapeutics Ltd is a biotechnology company focused on pharmaceutical drug development in oncology. The company has a portfolio of development candidates across various technologies targeting multiple cancer indications. Its primary program is Paxalisib, an investigational brain-penetrant inhibitor of the PI3K/Akt/mTOR pathway, designed for the treatment of brain cancer. The company develops targeted therapies aimed at addressing medical needs in oncology. The company operates in Australia and the United States.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 6
Valuation
|
Metric
|
KZIA
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 4.25 |
Price/Sales | 960.34 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
KZIA
|
|---|---|
Quick Ratio | 2.86 |
Current Ratio | 2.87 |
Interest Coverage | — |
Quick Ratio
KZIA
Profitability
|
Metric
|
KZIA
|
|---|---|
Return on Assets (Normalized) | −38.68% |
Return on Equity (Normalized) | −107.05% |
Return on Invested Capital (Normalized) | −106.74% |
Return on Assets
KZIA
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| Jycdqjwhs | Qxchwk | $113B | |||
| Regeneron Pharmaceuticals Inc
REGN
| Fkqdjpl | Xtwkrm | $64B | |||
| argenx SE ADR
ARGX
| Cjlmzxth | Cxy | $56B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| Bvwmgsjz | Vxwjkd | $39B | |||
| Royalty Pharma PLC Class A
RPRX
| Fktlrbvkf | Jwqzcy | $25B | |||
| BioNTech SE ADR
BNTX
| Zkttbkv | Zmxmd | $23B | |||
| Incyte Corp
INCY
| Srvwcbtml | Kmxp | $22B | |||
| Moderna Inc
MRNA
| Qrsbvqgm | Zlf | $20B | |||
| Jazz Pharmaceuticals PLC
JAZZ
| Tvpjnbfb | Tmjz | $15B | |||
| BridgeBio Pharma Inc
BBIO
| Jhlbglgc | Jwnm | $13B |
United States